Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What broker are you using? It's been showing in my Fidelity news feed since before the market opened.
Clearly you don't read the press releases. Todos offers multiple tests in their package. The rapid blood test is the one that will allow screening of the masses. The PCR test is the confirmatory test. With all the recent bad press on both antibody and PCR tests of other companies, including Abbot Labs, taking the time to validate the test results before bringing to market is going to benefit sales of their testing solution. To anyone capable of basic math, the hundreds of millions of tests needed cannot possibly be handled by the major players. The logistics don't support it. Todos should do well in this space.
Are you still holding your AMBS shares? Just curious if you, like JCacciabeve, enjoy trashing the investment where you still own shares.
Here you go, JPetro, some competition for the troubled Abbott Labs test. AMBS joint venture info in RED. Success of Todos Medical should have positive impact on Amarantus.
Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests
https://www.marketwatch.com/press-release/todos-medical-announces-first-commercial-sale-of-covid-19-antibody-tests-2020-05-18-71844528?mod=mw_quote_news
REHOVOT, Israel, May 18, 2020 (GLOBE NEWSWIRE via COMTEX) --
• Sub-distributor has network of state and local government clients seeking testing solutions
• Return to Church program being initiated in Orlando, Fla. area
REHOVOT, Israel, SINGAPORE and NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer's disease, today announced its first commercial sale of COVID-19 tests. The sale was made via a sub-distribution agreement with a U.S.-based medical distribution company with clients in state and local governments throughout the Southeastern United States who are seeking comprehensive testing solutions for Return-to-Work programs. Todos' sub-distributor's first sale was for rapid IgM/IgG fingerprick antibody test kits that will be deployed over Memorial Day weekend for the first of several Return to Church programs being planned. Todos' sub-distributor's church network covers over 84,000 Christian church congregations reaching over 28 million Americans.
"This sub-distribution agreement gives Todos' U.S. distribution division access to a network of state and local governments, as well as Christian churches, and other communities of faith, that are for the first time pursuing COVID-19 testing services as they seek to responsibly reopen their congregations," said Gerald E. Commissiong, President & CEO of Todos Medical. "We provide organizations and their lab partners with access to a comprehensive, steady supply of bundled, high-quality, FDA-compliant PCR and antibody testing solutions that address their needs as they implement COVID-19 testing programs. As private organizations begin to take control of their COVID-19 testing, Todos plans to be a solutions provider for both organizations and labs seeking to more efficiently administer COVID testing in the United States."
About the SARS-CoV-2 Coronavirus (COVID-19)
Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses can be transmitted between animals and people and evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, Hubei Province of China, and additional cases have been found in a growing number of countries worldwide. COVID-19 is the disease caused by SARS-CoV-2.
About Todos Medical Ltd.
Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa(R) breast cancer blood test. The transaction is expected to close in the second quarter of 2020.
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020.
Todos recently entered into distribution agreements with China-based companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements covering the U.S. and Israel with Gibraltar Brothers & Associates, LLC, a U.S.-based subsidiary of Shanghai Liangrun Biomedicine Technology Co. (Shanghai), for its proprietary colloidal gold immunochromatography (Colloidal Gold) point-of-care IgM/IgM-based antibody test kits, and with 3DMedicine Science & Technology Co (3DMed), a China-based cancer precision medicine company, for distribution in the U.S. and Israel of its ANDiS(R) SARS-CoV-2 Detection Kit (COVID), ANDiS(R) SARS-CoV-2 & Influenza A/B Detection Kit (COVID/Flu) and its proprietary ANDiS(R)350 3DMed Automated Solution countertop real-time PCR machine (3D Machine). Todos has formed Corona Diagnostics, LLC, a joint venture with Emerald Organic Products, Inc. (OTC: EMOR), to support the commercialization of its COVID-19 testing paradigm.
Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests
https://www.marketwatch.com/press-release/todos-medical-announces-first-commercial-sale-of-covid-19-antibody-tests-2020-05-18-71844528?mod=mw_quote_news
REHOVOT, Israel, May 18, 2020 (GLOBE NEWSWIRE via COMTEX) --
• Sub-distributor has network of state and local government clients seeking testing solutions
• Return to Church program being initiated in Orlando, Fla. area
REHOVOT, Israel, SINGAPORE and NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer's disease, today announced its first commercial sale of COVID-19 tests. The sale was made via a sub-distribution agreement with a U.S.-based medical distribution company with clients in state and local governments throughout the Southeastern United States who are seeking comprehensive testing solutions for Return-to-Work programs. Todos' sub-distributor's first sale was for rapid IgM/IgG fingerprick antibody test kits that will be deployed over Memorial Day weekend for the first of several Return to Church programs being planned. Todos' sub-distributor's church network covers over 84,000 Christian church congregations reaching over 28 million Americans.
"This sub-distribution agreement gives Todos' U.S. distribution division access to a network of state and local governments, as well as Christian churches, and other communities of faith, that are for the first time pursuing COVID-19 testing services as they seek to responsibly reopen their congregations," said Gerald E. Commissiong, President & CEO of Todos Medical. "We provide organizations and their lab partners with access to a comprehensive, steady supply of bundled, high-quality, FDA-compliant PCR and antibody testing solutions that address their needs as they implement COVID-19 testing programs. As private organizations begin to take control of their COVID-19 testing, Todos plans to be a solutions provider for both organizations and labs seeking to more efficiently administer COVID testing in the United States."
About the SARS-CoV-2 Coronavirus (COVID-19)
Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses can be transmitted between animals and people and evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, Hubei Province of China, and additional cases have been found in a growing number of countries worldwide. COVID-19 is the disease caused by SARS-CoV-2.
JPetro, the Abbott Labs test you posted about isn't fairing too well with the FDA.
Abbott’s Virus Test Has Potential Accuracy Issues, FDA Warns
https://www.bloomberg.com/news/articles/2020-05-15/abbott-coronavirus-test-has-potential-accuracy-issues-fda-warns
Abbott’s Virus Test Has Potential Accuracy Issues, FDA Warns
https://www.bloomberg.com/news/articles/2020-05-15/abbott-coronavirus-test-has-potential-accuracy-issues-fda-warns
I hope I don't lose my investment in AMBS. Some elite investors here have claimed the CEO is a liar and thief, yet they continue to hold their AMBS shares. I'm confused and not sure what to believe.
I'm in the same boat. I had the opportunity to sell at a decent profit, but thought it would go higher and now I'm at a loss. I have about $10K invested and would be okay at this point to just break even. Holding a little longer to see what happens. Penny stocks are pure speculative plays, in my book.
Yes, but with the proposed range of 1:10 to 1:100 it would be better for shareholders if the ratio was minimal. I did some digging into a 1:150 RS done by this CEO in Amarantus Bioscience in order to uplist to Nasdaq. It didn't go well. The uplist never occurred, and the share price drifted lower and is currently in the toilet. I would speculate the lack of revenues was a major driver in what happened there. If Todos conducts the RS after revenue is being generated from the COVID-19 test kits, the share price will likely be higher and result in a lower RS ratio. Growing revenue streams in this RS could have a different outcome than what happened with Amarantus. Hopefully this CEO learned from that failure and will not make the same mistake again. The RS needs revenues to support the post-RS share price, so I wouldn't expect a RS until sometime after significant revenue generation is announced. If it happens in that order, then I expect the uplist to Nasdaq will be positive for shareholders.
Roily23, my point was the May 11, 2020 end date for the RS stated in yesterday's 6K did not match the date stated in the proposal provided to shareholders prior to voting. That notice stated the RS could be completed no later than one year after the RS was approved. Since it was approved 5/11/20 the RS has to be completed by 5/11/21. The date in yesterday's 6K was an error. It doesn't agree with the terms of the proposal shareholders voted on. I notified the company of the error.
There is clearly an error in today's 6K. From the NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS:
https://investor.todosmedical.com/sec-filings/all-sec-filings##document-181-0001493152-20-006402-2
FDA approval of the Gnomegen COVID-19-RT-qPCR Detection Kit can be verified here:
https://www.fda.gov/media/137892/download
Why not buy more shares at this low low price, to add to the shares you currently hold? Lower your average price per share.
Clearly you don't believe this is a total scam if you're still holding shares.
I'm considering buying 1 share for a penny so I have a legitimate reason to post here, and so I won't be constantly attacked for not owning shares (but then I'd be like JP). Maybe I can become a moderator. Is share ownership required for that as well?
Happy Mothers Day!!
I received my proxy notice about two weeks ago from Fidelity. I voted against the RS. Probably won't matter.
You can vote online in 5 minutes, so why would your vote be late?
BREAKING NEWS FLASH: Penny stocks are speculative plays, not investments. Investing 101.
Nobody wants help from someone who sunk hundreds of thousands of dollars in a penny stock, lost it, and for years afterwards posts on message boards about the CEO beings a scam artist, and taking no personal responsibility at all for their own role in losing their "investment". What kind of advice could this person possibly give to others, except to stay away from penny stocks?
Just my opinion.
Yes, we can disagree. Still, I find it hard to imagine how anyone could remain invested in a company when they believe the CEO is dishonest, incompetent and a sleaze bag. And how is said dishonest, incompetent sleaze bag CEO going to pull off a win with Todos? Doesn't make much sense to remain invested with those beliefs, IMHO.
I fail to see how listing some of JP's enthusiasm about AMBS made your point that he is the only guy who has been right regarding AMBS. Seems quite the opposite. I'm not attacking him or you over that point. I agree with your point that investor sentiment changes over time. While he may be right about AMBS based on current share price or lack of progress, I suspect that outlook would change if Todos scored big with the coronavirus testing strategy they are pursuing, or if Amarantus scored a win with MANF or Lympro or their ESS product.
It's funny how money, winning or losing it, changes outlooks. And many people never accept their own role in their decisions, whether is was lack of due diligence or being blinded by the opportunity to make potentially a large gain if the investment succeeds. I have fallen victim to that as well. Most sensible investors wouldn't invest in penny stocks in the first place, but the lure of huge gains tends to blind the risks involved. Then it becomes a blame the CEO game for many. In my review of prior postings, I noticed several where JP claimed Gerald and Dad were living modest lives and putting everything into their company, and later on those posts changed to Gerald living the high life on the backs of scammed investors. It doesn't seem realistic for both to occur. More likely the perception changed when the personal investment losses mounted.
Incompetence or inexperience in dealing with vulture micro-cap funders? Dishonesty how? In regulatory filings, or in putting out overly optimistic expectations? Dishonesty in reporting generally lands a company in SEC regulatory violations and criminal charges or trading halts on the stock. I haven't seen either of those in the stock history, so it must be related to expectations. Just asking for clarification. I can excuse inexperience if the lessons learned from the mistakes aren't carried forward.
Good point about Israeli biotechs. Last RS by this CEO in Amarantus didn't go well. Looking back, the difference then was no revenue stream to support post-RS share price. Corona virus test kit revenues may give any RS done with Todos a greater chance of success. GLTA.
Thanks, but I plan to exit prior to any RS that may occur. Too many uncertainties in that. Will re-evaluate reinvesting afterwards. I am aware of AMBS RS a number of years ago. Didn't go well. Maybe this time it will, if revenues are being generated from test kits to stabilize price. Would rather see them grow business organically but what do I know? My background is science, not business, certainly not small cap business. Lots of issues to overcome in that arena.
As I posted on 3/30, demand is expected to be in the hundreds of millions of quick tests in the USA alone, thereby creating an opportunity for many different companies to participate in meeting that demand.
The at-home test kits you mentioned still require days before results are determined. While that will certainly be used by many, the 10-minute test is expected to become the primary means of screening the mass population, which is why so many companies are pursuing it. Agreed, a sense of urgency is needed, but so is validation testing to ensure results claimed by the Chinese manufacturers can be duplicated in the U.S. Todos seems to be taking steps necessary to get a solid piece of this testing pie, not the entire pie. There's room for everyone when multiple testing of every person is expected to become the norm... billions of tests needed worldwide. No single company will dominate. Many will share in that regard. Hopefully Todos will be a part of that, given their world-wide distribution license. Amarantus should benefit from the JV with Todos.
I understand the history and that many here have been burned. But many success stories have a history of failures in their past. Maybe that will be the story here. Maybe not. One thing is certain: there are some here who are so jaded by the past they will never see anything that unfolds as a possible path to any measure of success.
Read my earlier post with the link to today's press release. Yes, IGg and IGm methodologies.
Home testing kits may be readily accepted by the public, but I doubt the FDA will allow such tests without having medically-trained personnel involvement to interpret the results. The average Joe citizen doesn't understand the meaning of sensitivity and specificity numbers. Certainly any individual clearance being proposed will require the test be administered by medical professionals, not with a home test kit. I don't recall Todos mentioning pursuing home testing in any of their prior news releases.
Anything China is a no go... What do you mean?
Other biotech/medical companies are importing and selling China-based COVID-19 test kits. Aytu Bioscience is one example. It's true some of the Chinese-based tests have proven to be inaccurate, but Todos is validating their selected tests in Provista's CLIA lab before offering for sale. Smart move, in my opinion. Not first to the COVID-19 testing party, but will help to avoid any FDA restrictions or SEC intervention some other companies importing these tests are now facing.
The 96.5% sensitivity and 97.5% specificity validated results announced today are pretty impressive, and better than many of the claims of competing tests. Their strategy of offering a package of validated tests using different methodologies may differentiate them from their competitors and drive sales. Time will tell.
Give it time. The impact is not immediate, for either company, but you already know that.
I see the fascination with GC continues.
Man-Crush? GDS? Or both?
Emerald Organic is providing financing for the COVID-19 JV with Todos.
From the March 24, 2020 press release:
https://investor.todosmedical.com/news-events/press-releases/detail/44/coronavirus-covid-19-focused-joint-venture-formed-between
https://finance.yahoo.com/news/todos-medical-announces-positive-data-132211916.html
Todos Medical Announces Positive Data for Serology Point-of-Care Fingerprick Antibody Test Kits
Update coming next week.
Amarantus, which is now a holding company with multiple subsidiaries, has a history of investor losses and the same CEO as Todos. The AMBS board is moderated by an investor who lost money and has made it his life's mission to attack the CEO and company and try to steer anyone new to the stock away from it. I call it GDS (Gerald Derangement Syndrome). He's a sad, condescending prick who frequently refers to posters as son or sonny boy in his replies. Sad, really.
Also there are numerous investors who lost money still posting there attacking any post that tries to shed positive light on latest developments in the company. Those elements probably have something to do with the lack of interest in AMBS.
I will make more on my pocket change investment than you made in AMBS. That is clear. At least I will be able to move past it if I lose money. Get some help with that GDS thing, old-timer.
If you don't like the seedy underground world of penny stock financiers, why do you invest in penny stocks?
How do you know Gerald is continuing a lavish lifestyle? Are you keeping tabs on the man or is this just an assumption? An earlier poster stated Gerald had been wearing the same suit and tie, and living apart from his wife and kids for the past 5 years. That doesn't sound like a life of luxury. GDS?
Are you currently invested in AMBS? If not, then you shouldn't be posting here per your logic. If you are, then what does that say about someone slamming their own investment as much as you do? GDS?
Did you mean lose money (vs loose)? Did your educational system fail you?
You can't make this stuff up - too damn funny. GDS
No, you only attacked the character and intentions of the CEO of TOMDF, also CEO of AMBS. My facts are straight. I'm glad you have the keyboard courage to continue calling me son. Doubt it would be so if we were face to face.
And your inability to answer when challenged by another poster speaks volumes as to the accuracy of your claims.
Trump haters have what is labeled TDS. I suppose your condition could be labeled GDS. I would recommend seeking professional help, but we both know that's not gonna happen. LOL
You make claims against the CEO of AMBS and TOMDF and then refuse to answer simple questions when challenged. I am not spamming. My questions are relevant to AMBS because your posts attack the character and intentions of the CEO, who just happens to be running both companies.
Tossing out the "spam card" seems very weak in response. Back up your claims by answering the questions I posted. Or go hide under mama's skirt. Your choice.
Let me say this again. I have no investment in AMBS, only in TOMDF where a reverse split has already been put to shareholder vote but not yet approved. So I know it's coming and will likely sell before that occurs. Possibly get back in afterwards depending on what develops. AMBS has a sizable stake in TOMDF shares. If that company succeeds then AMBS share value should also rise.
Please elaborate on the claims you previously made. I asked these questions in my last post, which you ignored.
NBC just now reporting on a competitor's COVID-19 antibody test that was not approved in China as originally thought, and has already been distributed for use in USA.
Unapproved Chinese coronavirus antibody tests being used in at least 2 states
Some Chinese-made COVID-19 antibody tests being used in the U.S. were not approved by China's FDA.
China has now barred their export.https://www.nbcnews.com/health/health-news/unapproved-chinese-coronavirus-antibody-tests-being-used-least-2-states-n1185131
The Todas approach may appear to be slower, but they seem to be taking the necessary steps to ensure they don't fall into the same trap. The other company's stock is getting hammered in after hours trading.
You clearly don't like the Amarantus CEO. I can understand that if you lost money in your investment.
I received a message from an investor suggesting I ask you about a "Come to Jesus" conversation you had with Gerald, and your attempts to rally support from shareholders. What was that about?
Added as well, but at 0.10
Amarantus has a stake in Todas Medical. That makes what happens with Todas relevant to Amarantus shareholders, whether you like it or not.
Is your goal to prohibit any discussion that might suggest a rise in AMBS share price, or simply to warn potential investors away from this company's shares no matter what is unfolding, good or bad?
The Provista acquisition requires the company be listed on a national exchange and the acquisition is still planned for 2nd quarter 2020. So it seems clear any RS approved by shareholders will occur sometime this quarter. This is all spelled out in the 6-K filings.
If the company can start generating sales from the COVID-19 tests in the next 2 months and drive the share price higher, the RS ratio should be minimized. It seems reasonable this would be the plan for the uplist, with each piece falling into place as we are seeing it happen.